Catalyst Pharmaceuticals Inc (CPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($59.59 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CPRX market cap overview for the company's overall valuation and market capitalisation.
Catalyst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Catalyst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Catalyst Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yuhan Corp.
KO:000100
|
0.003x |
|
BW LPG Ltd
OL:BWLPG
|
0.310x |
|
Aoshikang Technology Co Ltd Class A
SHE:002913
|
-0.001x |
|
SiteOne Landscape Supply Inc
NYSE:SITE
|
0.091x |
|
Mirion Technologies Inc
NYSE:MIR
|
0.031x |
|
Aya Gold & Silver Inc. Common Shares
NASDAQ:AYA
|
0.095x |
|
Doosan Bobcat Inc
KO:241560
|
0.034x |
|
KLCC Property Holdings Bhd
KLSE:5235SS
|
0.021x |
Annual Cash Flow Conversion Efficiency for Catalyst Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Catalyst Pharmaceuticals Inc from 2004 to 2025. View Catalyst Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $954.27 Million | $208.67 Million | 0.219x | -33.65% |
| 2024-12-31 | $727.63 Million | $239.81 Million | 0.330x | -10.98% |
| 2023-12-31 | $387.88 Million | $143.60 Million | 0.370x | -4.16% |
| 2022-12-31 | $300.42 Million | $116.05 Million | 0.386x | +32.34% |
| 2021-12-31 | $206.83 Million | $60.37 Million | 0.292x | +9.92% |
| 2020-12-31 | $169.60 Million | $45.03 Million | 0.266x | -32.77% |
| 2019-12-31 | $87.63 Million | $34.61 Million | 0.395x | +178.03% |
| 2018-12-31 | $50.78 Million | $-25.70 Million | -0.506x | -198.20% |
| 2017-12-31 | $80.96 Million | $-13.74 Million | -0.170x | +62.86% |
| 2016-12-31 | $39.31 Million | $-17.96 Million | -0.457x | -40.72% |
| 2015-12-31 | $55.48 Million | $-18.02 Million | -0.325x | +11.57% |
| 2014-12-31 | $35.24 Million | $-12.94 Million | -0.367x | +20.46% |
| 2013-12-31 | $21.39 Million | $-9.88 Million | -0.462x | -31.32% |
| 2012-12-31 | $14.62 Million | $-5.14 Million | -0.352x | +73.48% |
| 2011-12-31 | $3.76 Million | $-4.99 Million | -1.326x | -94.66% |
| 2010-12-31 | $5.52 Million | $-3.76 Million | -0.681x | +32.48% |
| 2009-12-31 | $7.62 Million | $-7.68 Million | -1.009x | -28.94% |
| 2008-12-31 | $10.56 Million | $-8.26 Million | -0.782x | -188.55% |
| 2007-12-31 | $16.32 Million | $-4.42 Million | -0.271x | -356.52% |
| 2006-12-31 | $19.85 Million | $-1.18 Million | -0.059x | +94.18% |
| 2005-12-31 | $446.46K | $-455.36K | -1.020x | +47.98% |
| 2004-12-31 | $117.58K | $-230.52K | -1.961x | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more